

To the shareholders of Zelluna ASA

**Recommendations by the Nomination Committee to the
Extraordinary General Meeting on 9 September 2026:**

Background

Hans Ivar Robinson has informed the Board that he will step down as a member of the Board of Directors. He co-founded the Company and has been a key contributor to its development through successive phases over more than a decade. His resignation follows Birk Venture's policy of retiring from board positions within a reasonable period following a listing.

Recommendation

The Nomination Committee recommends that Martin Welschhof be elected as a new member of the Board of Directors for the remainder of the current term, expiring at the Annual General Meeting in 2027. His term will thereby be aligned with that of the other shareholder-elected members of the Board.

Basis for the recommendation

Martin Welschhof brings extensive experience as CEO of both private and listed clinical-stage biotech companies, an established international network across the pharmaceutical industry and the investor community, and experience from transactions and from operating in a listed environment. The Nomination Committee considers that his background will strengthen the Board's competence in areas of central importance to the Company's strategy.

Martin Welschhof is considered independent of the Company's executive management and major shareholders. He has confirmed his willingness to accept election.

A short biography is attached.

The proposal below has been unanimously resolved by the Nomination Committee.

Oslo, 16 August 2026

On behalf of the Nomination Committee

Jónas Einarsson (chair)

Hans Peter Bøhn

Martin Welschhof

Martin brings over three decades of international biotech leadership, combining deep scientific expertise with a track record of building, partnering and financing clinical-stage companies in public markets.

He is currently CEO of BioInvent International AB (Nasdaq Stockholm), a clinical-stage immuno-oncology company. He has previously served as CEO of Affitech A/S (Nasdaq Copenhagen) and CEO of Opsona Therapeutics (Dublin), and as Director of Technology at Axaron Bioscience AG (Heidelberg), giving him hands-on experience of leading listed life science companies through clinical development, partnering and capital raising.

Martin holds a PhD (Dr. rer. nat.) in recombinant antibody technology and completed postdoctoral training at the German Cancer Research Center (DKFZ), Department of Recombinant Antibody Technology, and at the University of Heidelberg, Department of Transplantation Immunology. He is a recognised authority in the field and complements his executive experience with extensive board service.